Clinical trials: Dyskinesia
Alzheimer's Disease
Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
The purpose of this study is to determine whether this drug can help symptoms of aggression and agitation in participants with Alzheimer's disease.
- Trial name
- NCT00843518
- Testing
- LY451395
- Where
- 17 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
- Trial name
- NCT07365462
- Testing
- NBI-1065890
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- Neurocrine Biosciences
Huntington Disease
Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease
This study will investigate if a new experimental drug to treat Huntington's Disease gets into the brain. If it does get into the brain the study will explore the relationship between the amount of drug in the brain and the…
- Trial name
- NCT01602900
- Testing
- GSK356278, Rolipram
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Trial name
- ADVANCE-2 (NCT05557409)
- Testing
- AXS-05
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 408 people
- Sponsor
- Axsome Therapeutics, Inc.
Tourette Syndrome
A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome
This is an open-label study of SNC-102 (acamprosate calcium sustained release tablet) in adult subjects with Tourette Syndrome. Subjects will be treated with oral doses of SNC-102 800 mg on a BID basis - before breakfast and at…
- Trial name
- NCT02217007
- Testing
- SNC-102 sustained release tablet
- Where
- 2 sites in United States
- Sponsor
- Synchroneuron Inc.
Huntington Disease
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.
- Trial name
- INVEST-HD (NCT07326709)
- Testing
- Votoplam (blinded)
- Where
- 117 sites in United States, Argentina and 25 more
- Volunteers
- 770 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196
The primary objective of this study is to provide biological samples from patients with Huntington's disease to allow characterisation of the pharmacological mechanism of action of SEN0014196.
- Trial name
- PADDINGTON (NCT01485952)
- Testing
- SEN0014196 (Low Dose), SEN0014196 (High Dose)
- Where
- Germany
- Volunteers
- 55 people
- Sponsor
- Siena Biotech S.p.A.
Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children
MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia
Ataxia Telangiectasia (A-T) is an autosomal recessively inherited neurodegenerative disorder that also has dramatic effects on the immune and endocrine systems.
- Conditions
- Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children, Ataxia Telangiectasia
- Trial name
- NCT04887311
- Testing
- MBM-01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Matrix Biomed, Inc.
Dyskinesias, Parkinson Disease
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
This study will assess the efficacy and safety of modified release AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders
- Trial name
- NCT01491529
- Testing
- AFQ056
- Where
- 39 sites in United States, Austria and 8 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Movement, Involuntary
NIBP (Non-invasive Blood Pressure) Algorithm Enhancements (Characterize the Robustness of Motion Artifact Suppression)
The study intervention consists of a non-invasive blood pressure (NIBP) measurement device and cuff (FDA-cleared Philips IntelliVue X3 Rev.
- Trial name
- NCT05185037
- Testing
- Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Tardive Dyskinesia
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective…
- Trial name
- NCT01267188
- Testing
- NBI-98854
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Neurocrine Biosciences
Stroke, Dystonia
MyoSense- Automated Muscle Hypertonicity Classification System
It is often difficult to quantify and distinguish aspects of abnormal muscle tone due to neurological injury. This makes it difficult to evaluate therapies that aim to reduce the effects of abnormal muscle tone.
- Conditions
- Stroke, Dystonia, Cerebral Palsy
- Trial name
- NCT02076581
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
Automated Telehealth Diagnostics for Remote Parkinson Monitoring
The objective is to clinically assess the Kinesia HomeView system for automated and remote monitoring of Parkinson's disease (PD) motor symptoms.
- Trial name
- PDRemote (NCT02152319)
- Testing
- KHV reporting, Standard care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease, Tolerability
Safety and Tolerability Study Evaluating ACR325 in Parkinson's Disease Patients
The study will evaluate the safety and tolerability of ACR325 in Parkinson disease patients and evaluate the effect on levodopa induced dyskinesias.
- Trial name
- NCT01023282
- Testing
- ACR325
- Where
- 2 sites in Germany
- Volunteers
- 22 people
- Sponsor
- NeuroSearch A/S
Parkinson's Disease (PD)
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
The primary objective of this study was to examine the effect of levodopa-carbidopa intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in participants with advanced Parkinson's disease (PD).
- Trial name
- DYSCOVER (NCT02799381)
- Testing
- Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump
- Where
- 28 sites in United States, Finland and 5 more
- Volunteers
- 63 people
- Sponsor
- AbbVie
Parkinson Disease, Essential Tremor
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
The primary objective of this study is to characterize real-world clinical outcomes of Deep Brain Stimulation (DBS) using retrospective review of de-identified patient records.
- Conditions
- Parkinson Disease, Essential Tremor, Dystonia
- Trial name
- NCT03664609
- Testing
- Deep Brain Stimulation
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 5,000 people
- Sponsor
- Boston Scientific Corporation
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Cerebral Palsy, Dyskinetic
A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents
CP (cerebral palsy) refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement and muscle coordination.
- Trial name
- RECLAIM-DCP (NCT03813238)
- Testing
- TEV-50717
- Where
- 70 sites in United States, Belgium and 10 more
- Volunteers
- 63 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Rett Syndrome
A Safety Study of NNZ-2566 in Pediatric Rett Syndrome
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Rett syndrome in children and adolescents.
- Trial name
- NCT02715115
- Testing
- NNZ-2566
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Neuren Pharmaceuticals Limited